We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Store » FDA Seeks More Data on Forest and Gedeon Richter’s Schizophrenia Drug
FDA Seeks More Data on Forest and Gedeon Richter’s Schizophrenia Drug
$25.00
Product Details
The FDA has handed Forest Laboratories and Gedeon Richter a complete response letter asking for more data on cariprazine, the companies’ drug candidate to treat schizophrenia and manic or mixed episodes of bipolar I disorder in adults.